2021
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysTargeting Peripheral T-Cell Lymphoma Epigenome
Scotto L, Kinahan C, Douglass E, Deng C, Safari M, Casadei B, Marchi E, Lue JK, Montanari F, Falchi L, Qiao C, Renu N, Bates SE, Califano A, O'Connor OA. Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysTargeting Peripheral T-Cell Lymphoma Epigenome. Molecular Cancer Therapeutics 2021, 20: 1422-1430. PMID: 34108263, PMCID: PMC8941846, DOI: 10.1158/1535-7163.mct-20-0377.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmAntimetabolites, AntineoplasticApoptosisAzacitidineBiomarkers, TumorCell ProliferationDNA (Cytosine-5-)-Methyltransferase 1DNA MethylationEpigenesis, GeneticEpigenomeGene Expression ProfilingGene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsHumansImmunityLymphoma, T-CellMaleTestisTumor Cells, CulturedConceptsEpigenetic geneHistone deacetylaseSuppression of genesHDAC inhibitorsDNA methyltransferase inhibitorTranscriptional inductionDNA methylationMaster regulatorDNMT inhibitorsEpigenetic diseasePeripheral T-cell lymphomaGene expressionMethyltransferase inhibitorMechanistic basisCell deathGenesCancer-testis antigensTestis antigensEpigenomeMutationsCholesterol metabolismInhibitorsInductionMatrisomeTh1-like phenotype
2020
Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers
Scotto L, Kinahan C, Casadei B, Mangone M, Douglass E, Murty VV, Marchi E, Ma H, George C, Montanari F, Califano A, O'Connor OA. Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers. Genes Chromosomes And Cancer 2020, 59: 639-651. PMID: 32614991, PMCID: PMC7540375, DOI: 10.1002/gcc.22884.Peer-Reviewed Original ResearchConceptsDihydrofolate reductaseResistant cell linesGene expression profilesCell linesT-cell lymphoma lineAntifolate pharmacologyEpigenetic modifiersExpression analysisGene expressionExpression profilesMechanistic basisT-cell selectivityParental H9 cellsIncreases expressionT-cell lymphomaSTAT5 phosphorylationMolecular targetsGene amplificationConcentration-dependent fashionLymphoma linesH9 cellsDrug resistancePutative mechanismsCellsPutative biomarkers
2015
Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Montanari F, Diefenbach CS. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy. Clinical Advances In Hematology And Oncology 2015, 13: 518-24. PMID: 26351815.Peer-Reviewed Original ResearchConceptsClassical Hodgkin lymphomaCHL microenvironmentAutologous stem cell transplantLong-term disease controlTumor microenvironmentHeterogeneous inflammatory infiltratesReed-Sternberg (HRS) tumor cellsFirst-line therapyStem cell transplantAdvanced-stage patientsNew biologic insightsRelapsed patientsCell transplantInflammatory infiltrateHodgkin's lymphomaClinical trialsTherapeutic strategiesTumor growthTumor cellularityDisease controlNovel antitumor strategyBiologic insightsHRS cellsTumor cellsAntitumor strategy